Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 3/20 | 0.43 |
| ▸ | DDO | Q99489 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21230721 | 0.76 | PARP1 (0.48) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL7023394 | 0.76 | CA12 (0.39) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL13857874 | 0.76 | PARP1 (0.48) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL6199860 | 0.76 | PARP1 (0.67) | CA12CA9PARP1KDM4EALDH1A1 | |
| SCHEMBL5332369 | 0.76 | EGFR (0.50) | CA12CA9PARP1KDM4EAR | |
| SCHEMBL2731038 | 0.76 | PARP1 (0.48) | CA12CA9PARP1KDM4ETYMP | |
| SCHEMBL2919116 | 0.76 | CHEK1 (0.53) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL2922284 | 0.76 | DAO (0.60) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL20954833 | 0.76 | KDM4E (0.57) | CA12CA9PARP1KDM4EDAO | |
| SCHEMBL12836460 | 0.75 | FEN1 (0.52) | FEN1CA12CA9PARP1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS INC (CN) | 2018-08-02 | — | — | US | disclosed |
| US-9926304-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290460-B2 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| EP-2709990-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics, Inc. (CN) | 2014-03-26 | — | — | EP | disclosed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | disclosed |
| WO-2012130166-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012014109-A1 | HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0775697-B1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5994542-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0878468-A1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5756738-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0775697-A1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | FEN1 182/4885CA12 4868/4885CA9 4321/4885 |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | FEN1 175/4885CA12 4862/4885CA9 4276/4885 |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | FEN1 182/4885CA12 4868/4885CA9 4321/4885 |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | FEN1 175/4885CA12 4862/4885CA9 4276/4885 |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | FEN1 182/4885CA12 4868/4885CA9 4321/4885 |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | FEN1 206/4885CA12 4859/4885CA9 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.